Armed With An FDA-Cleared IND, TLS Sets Out To Democratize Clinical Trials
Executive Summary
Transparency Life Sciences applies crowdsourcing to the design of clinical protocols with the aim of lowering costs and improving outcomes for clinical trials. The company won FDA clearance for its first IND based on a protocol that resulted from its process and is securing its first financing.
You may also be interested in...
Atlas, CMEA Test New Biotech Model
Two high-profile VCs, CMEA Capital and Atlas Venture, are trying their hands at asset financing, an investment strategy that prioritizes single drug programs over companies and is becoming, at least theoretically, possible to do in a more systematic way. That's because big drug companies have cut internal R&D staff, often in drastic measure, and they want someone to share the development risk of drugs now sitting idle on their shelves.
Lilly's Web-Based Research Marketplace
Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with Innocentive LLC, a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing. Innocentive offers a means for pharmaceutical and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.